Home > Journals > Medicine > European Journal of Dermatology > summary
 
      Advanced search    Shopping cart    French version 
 
Latest books
Catalogue/Search
Collections
All journals
Medicine
European Journal of Dermatology
- Current issue
- Archives
- Subscribe
- Order an issue
- More information
Biology and research
Public health
Agronomy and biotech.
My account
Forgotten password?
Online account   activation
Subscribe
Licences IP
- Instructions for use
- Estimate request form
- Licence agreement
Order an issue
Pay-per-view articles
Newsletters
How can I publish?
Journals
Books
Help for advertisers
Foreign rights
Book sales agents



 

Texte intégral de l'article
 
Printable version

HHV-8 positive Kaposi sarcoma in a patient with end-stage renal disease undergoing hemodialysis: No regressive effect of captopril


European Journal of Dermatology. Volume 17, Number 2, 153-6, March-April 2007, Clinical report

Free Article  

Author(s) : Şirin Yaşar, Ayse Tülin Mansur, Fatih Göktay, Ikbal Esen Aydingöz

Summary : Human herpesvirus 8 (HHV-8) has been associated with Kaposi sarcoma (KS) in renal transplant recipients. On the other hand, there are only a few reported cases of KS in patients with end stage renal failure receiving hemodialysis. Here, we report a case of HHV-8 positive, dissseminated KS, in a 70-year-old man with renal failure, receiving hemodialysis for 7 months. The KS lesions had begun to develop almost at the same time with the onset of dialysis. The patient had been on captopril therapy since the diagnosis of renal failure. Captopril has been reported to inhibit angiogenesis, and by this way, to reduce tumor growth. However, in our patient, the lesions had developed under the treatment of captopril, and showed no evidence of regression after withdrawal of the drug.

Keywords : captopril, end-stage renal disease, hemodialysis, Kaposi sarcoma

 

About us - Contact us - Conditions of use - Secure payment
Latest news - Conferences
Copyright © 2007 John Libbey Eurotext - All rights reserved
[ Legal information - Powered by Dolomède ]